Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + Chemotherapy in ctDNA Negative Liver Metastatic CRC
NCT06490913Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Nov 2024
- Primary completion
- Jun 2025
- Sponsor
- Fujian Medical University Cancer Hospital
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Drugs
- cetuximab
- Conditions
- colorectal cancer (CRC)
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in colorectal cancer (CRC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective Response Rate. Planned start Nov 2024; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
cetuximab+chemotherapy
XELOX 1 cycle; cetuximab+chemotherapy up to 12 cycles
03
Who it enrols
Patients with liver metastases from RAS wild-type colorectal cancer and ctDNA superselective negative genes who have not received prior treatment.
04
Endpoints
Primary
Objective Response Rate
Secondary
Overall Survival
Beyond the preview
Go deeper on NCT06490913.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06490913.